http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
레이저포인터와 전방향 위치검출시스템을 이용한 로봇의 주행 지시 방법
류지형,김지홍,이창구 제어로봇시스템학회 2008 제어로봇시스템학회 합동학술대회 논문집 Vol.2008 No.12
Comparing with fixed-type Robots, Mobile Robots have the advantage of extending their workspaces But this advantage need some sensors to detect mobile robot"s position and find their goal point. This article describe the navigation teaching method of mobile roobt using laser pointer and omni-directional position detectino system. This system offers the brief data to a processor with simple devices. In these reason, we can reduce the time of a calculation to process of images and find the target by user point for carrying a robot User points a laser spot on a point to be moved so that this sensor system in the robot, detecting the laser spot point with a conic mirror, laid on the robot, showing a camera. The camera is attached on the robot upper body and fixed parallel to the ground and the conic mirror.
류지형,권민석,문정대,황민웅,이정민,박기현,윤소정,배현진,최애란,이혜영,정봉수,정주희,한경자,김용구,오은지 대한진단검사의학회 2018 Annals of Laboratory Medicine Vol.38 No.6
Background: Accurate, rapid, and cost-effective screening tests for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection may be useful in laboratories that cannot afford automated chemiluminescent immunoassays (CLIAs). We evaluated the diagnostic performance of a novel rapid automated fluorescent lateral flow immunoassay (LFIA). Methods: A fluorescent LFIA using a small bench-top fluorescence reader, Automated Fluorescent Immunoassay System (AFIAS; Boditech Med Inc., Chuncheon, Korea), was developed for qualitative detection of hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and antibody to HCV (anti-HCV) within 20 minutes. We compared the diagnostic performance of AFIAS with that of automated CLIAs—Elecsys (Roche Diagnostics GmbH, Penzberg, Germany) and ARCHITECT (Abbott Laboratories, Abbott Park, IL, USA)—using 20 seroconversion panels and 3,500 clinical serum samples. Results: Evaluation with the seroconversion panels demonstrated that AFIAS had adequate sensitivity for HBsAg and anti-HCV detection. From the clinical samples, AFIAS sensitivity and specificity were 99.8% and 99.3% for the HBsAg test, 100.0% and 100.0% for the anti-HBs test, and 98.8% and 99.1% for the anti-HCV test, respectively. Its agreement rates with the Elecsys HBsAg, anti-HBs, and anti-HCV detection assays were 99.4%, 100.0%, and 99.0%, respectively. AFIAS detected all samples with HBsAg genotypes A-F and H and anti-HCV genotypes 1, 1a, 1b, 2a, 2b, 4, and 6. Cross-reactivity with other infections was not observed. Conclusions: The AFIAS HBsAg, anti-HBs, and anti-HCV tests demonstrated diagnostic performance equivalent to current automated CLIAs. AFIAS could be used for a large-scale HBV or HCV screening in low-resource laboratories or low-to middle-income areas.